

# Ikke Småcellet Lungecancer





AARHUS UNIVERSITET


## Ikke Småcellet Lungecancer

Patologisk Institut  
Aarhus Universitetshospital





# Lunge Carcinom




Lunge carcinomer dannes fra stamceller i lungeepithelet



# Lunge Carcinom

Antal primære maligne lungetumorer i DK:






# Lunge Carcinom

## Leading Cancer Deaths

Estimated mortalities for 1999




SOURCE: American Cancer Society, 1999



# Lunge Carcinom


## 20-Year Lag Time Between Smoking and Lung Cancer






# Lunge Carcinom

Antal primære maligne lungetumorer i DK:







# Lunge Carcinom




## Stadium ved diagnose




# Lunge Carcinom




Adenocarcinom



Plancellulært carcinom



Storcellet carcinom




Småcellet carcinom

Non Small Cell Lung Carcinoma (NSCLC)

Ikke Småcellet carcinom




8.7.3 Fig. Patologityper per år - totalt:





# Udredning






70%

Not operabel

Operabel

30%



Central tumor





Periferal tumor

Tumor Diagnosis

Bronchial brushing,  
Bronchial lavage,

Fine- or  
Course n  
biopsi



Tumor type


Diagnosis of metastases

Fine needle  
aspiration

EBUS  
EUS<sup>N</sup>

M

areas (found by CT eller PET scan)






70%

Not operabel


Operabel

30%







Adenocarcinoma



Squamous carcinoma





Large cell carcinoma





Small cell carcinoma

Non Small Cell Lung Carcinoma  
(NSCLC)




Pathways of cancer




oncogenes







# Driver mutation





**Driver mutation**









# EGFR





# EGFR




*Tissue section*

*DNA<sub>(template)</sub>*

*DNA-purification*



*PCR*

*Analysis*





# EGFR



*Tissue section*

*DNA<sub>(template)</sub>*



*DNA-purification*

*PCR*

*Analysis*



# EGFR



Cytology specimen

DNA<sub>(template)</sub>


DNA-purification

PCR

Analysis




# EGFR



## Amplification Refractory Mutation System

Primer fits mutated sequence





Mutated DNA

Wild Type DNA


FIG. 1

## Scorpion probe







hvis muteret







## PFS according to type of EGFR activating mutation







# EML4-ALK




EML4



EML4-ALK v3b






ALK






# EML4-ALK







# EML4-ALK



## In Situ hybridisation






# EML4-ALK



## In Situ hybridisation





# EML4-ALK



## In Situ hybridisation





# EML4-ALK




## ALK brake apart probe





# EML4-ALK




hist




cyt




Hvis muteret






### B CT before and after Crizotinib



AP



# Lung cancer research landscape – MoA group and phase



# Fremtid



**The end**